Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Immunological analysis and characterization of lymphocyte subsets in specimens of human hepatocellular carcinomas and metastatic liver cancers

  • 19 Accesses

  • 4 Citations

Summary

The distribution and number of CD2 (Coulter T11)+ cells, CD16 (Leu 11b)+ cells, Leu 7+ cells, CD8 (OKT 8)+ cells, CD11 (Leu 15)+ cells, CD4 (Leu 3a+3b)+ cells and Leu 10+ or Leu 14+ cells in the liver of patients with hepatocellular carcinoma (HCC) and metastatic liver cancer (MLC) were investigated using monoclonal antibodies and immunohistological methods. In the majority of those with HCC and MLC, CD8 (OKT 8)+, Leu 7+ and CD16 (Leu 11b)+ cells were present both in the tumor and non-tumor tissues. The CD8 (OKT 8)+ cells were more numerous than Leu 7+ and CD16 (Leu 11b)+ cells. No significant difference was observed in the distribution and number of Leu 7+ and CD16 (Leu 11b)+ cells, in any area, in both groups. The number of CD8 (OKT 8)+ cells predominated in the non-tumor area, in both groups. CD11 (Leu 15)+ cells and CD8 (OKT 8)+ cells were present in the ratio of 1:3 or 1:4. The number of CD4 (Leu 3a+3b)+ cells was less than that of CD8 (OKT 8)+ cells in both groups, especially in the tumor area. A few Leu 10+ or Leu 14+ cells were present in all areas, in both groups. In most cases of MLC, the CD8 (OKT 8)+ cells were absent in the tumor area. There was no correlation between the distribution and number of these cells and anti-tumor chemotherapy or non-specific immunotherapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T (1983) Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 198:192

  2. 2.

    Balch CM, Dougherty PA, Cloud GA, Tilden AB (1984) Prostaglandin-E-mediated suppression of cellular immunity in colon cancer patients. Surgery 95:71

  3. 3.

    Balch CM, Itoh K, Tilden AB (1985) Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 98:151

  4. 4.

    Berret JT (1983) The B and T lymphocytes. In: Textbook of immunology, 4th ed. Mosby, St. Louis, p 77

  5. 5.

    Blace MM, Freeman C, Mork T, Harvei S, Cutler SJ (1971) Prognostic significance of microscopic structure of gastric carcinomas and their regional lymph nodes. Cancer 27:703

  6. 6.

    Brooks WH, Netsky MG, Normansell DE, Horwitz DV (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. J Exp Med 136:1631

  7. 7.

    Clement LT, Grossi CE, Gartland L (1984) Morphologic and phenotypic features of the subpopulation of Leu 2+ cells that suppresses B cell differentiation. J Immunol 133:2461

  8. 8.

    Damle NK, Doyle LV, Bradley EC (1986) Interleukin-2-activated human killer cells are derived from phenotypically heterogenous precursors. J Immunol 137:2814

  9. 9.

    Dickmeiss E, Soeberg A, Svejgaad A (1977) Human cell-mediated cytotoxicity against modified target cells is restricted by HLA. Nature 270:526

  10. 10.

    Ferrini S, Miescher S, Zocchi MR, Fliedner VV, Morreta A (1987) Phenotypic and functional characterization of recombinant interleukin 2 (rIL2)-induced activated killer cells: Analysis at the population and clonal levels. J Immunol 138:1297

  11. 11.

    Friedman SM, Hunter SB, Irigoyen OH, Kung PC, Goldstein G, Chess L (1981) Functional analysis of human T cell subsets defined by monoclonal antibodies. J Immunol 126:1702

  12. 12.

    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823

  13. 13.

    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymusderived lymphocytes, and natural killer cells. J Exp Med 157:884

  14. 14.

    Herberman RB, Djeu JY, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P (1979) Natural killer cells: characteristics and regulation of activity. Immunol Rev 44:43

  15. 15.

    Herberman RB, Ortaldo JR (1981) Natural killer cells: their role in defences against diseases. Science 214:24

  16. 16.

    Hojo H, Hashimoto Y (1981) Cytotoxic cells induced in tumor-bearing Jats by a streptococcal preparation OK-432. Jpn J Cancer Res 72:692

  17. 17.

    Husby G, Hoagland PM, Strickland RG, Williams RC Jr (1976) Tissue T and B cell infiltration of primary and metastatic cancer. J Clin Invest 57:1471

  18. 18.

    Iida F (1974) Stromal reaction in thyroid cancer. Jpn J Cancer Clin 20:617

  19. 19.

    Itoh K, Tilden AB, Kumagai K, Balch CM (1985) Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol 134:802

  20. 20.

    Itoh K, Tilden AB, Balch CM (1986) Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol 136:3910

  21. 21.

    Kai S, Tanaka J, Nomoto K, Torisu M (1979) Studies of the immunopotentiation effects of a streptococcal preparation OK-432: I. Enhancement of T-cell-mediated immune responces of mice. Clin Exp Immunol 37:98

  22. 22.

    Lafreniere R, Rosenberg SA (1985) Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rIL 2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J Immunol 135:4273

  23. 23.

    Landay A, Gartland GL, Clement LT (1983) Characterization of a phenotypically distinct subpopulation of Leu 2+ cells that suppresses T cell proliferative responses. J Immunol 131:2757

  24. 24.

    Mondelli M, Vergani GM, Alberti A, Vergani D, Portman B, Eddleston A, Williams R (1982) Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129:2773

  25. 25.

    Mondelli M, Eddleston ALWF (1984) Mechanisms of liver cell injury in acute and chronic hepatitis B. Semin Liver Dis 4:47

  26. 26.

    Morales A, Ottenhof PC (1983) Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer 52:667

  27. 27.

    Murgita RA, Tomasi TB Jr (1975) Suppression of the immune response by alpha-fetoprotein: II. The effect of mouse alphafetoprotein on mixed lymphocyte reactivity and mitogen induced lymphocyte transformation. J Exp Med 141:440

  28. 28.

    Oshimi K, Kano S, Takaku F, Okumura K (1980) Augmentation of mouse natural killer cell activity by streptcoccal preparation, OK-432. J Natl Cancer Inst 65:1265

  29. 29.

    Phillips JH, Lanier LL (1986) Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814

  30. 30.

    Reinherz EL, Kung PC, Goldstein G, Schlossman SF (1980) A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by heteroantiserum termed TH2. J Immunol 124:1301

  31. 31.

    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485

  32. 32.

    Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318

  33. 33.

    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889

  34. 34.

    Shimizu M, Yuh K, Aoyama S, Ichihara I, Watanabe H, Shijo H, Okumura M (1986) Immunohistochemical characterization of inflamatory infiltrates at the site of bile duct injury in primary biliary cirrhosis. Liver 6:1

  35. 35.

    Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K (1982) Identification of lymphocyte subpopulation in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer 49:1456

  36. 36.

    Si L, Whiteside TL (1983) Tissue distribution of human NK cells studied with anti-Leu-7 monoclonal antibody. J Immunol 130:2149

  37. 37.

    Si L, Whiteside TL, Van Thiel HD, Rabin BS (1984) Lymphocyte subpopulations at the site of “piecemeal” necrosis in end stage chronic liver disease and rejecting liver allografts in Cyclosporine-treated patients. Lab Invest 50:341

  38. 38.

    Simmons PJG, Oldstone MBA (1980) Antibody-mediated destruction of virus infected cells. Adv Immunol 29:209

  39. 39.

    Son K, Kew M, Rabson AR (1982) Depressed natural killer cell activity in patients with hepatocellular carcinoma. Cancer 50:2820

  40. 40.

    Taniyama T, Azuma I, Aladin AA, Yamamura Y (1975) Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice. Jpn J Cancer Res 66:705

  41. 41.

    Uchida A (1984) Intrapleural administration of OK-432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes. Cancer Immunol Immunother 18:5

  42. 42.

    Watanabe H, Enjoji M, Imai T (1976) Gastric carcinoma with lymphoid stroma: its morphologic characteristics and prognostic correlations. Cancer 38:232

  43. 43.

    Whittaker MG, Rees K, Clark CG (1971) Reduced lymphocyte transformation in breast cancer. Lancet I:892

  44. 44.

    Yuh K (1986) Lymphocyte subsets in human liver from patients with various liver diseases. Med Bull Fukuoka Univ 13:241

Download references

Author information

Correspondence to Masanori Shimizu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yuh, K., Shimizu, M., Aoyama, S. et al. Immunological analysis and characterization of lymphocyte subsets in specimens of human hepatocellular carcinomas and metastatic liver cancers. Cancer Immunol Immunother 28, 1–8 (1989). https://doi.org/10.1007/BF00205793

Download citation

Keywords

  • Carcinoma
  • Monoclonal Antibody
  • Cancer Research
  • Hepatocellular Carcinoma
  • Liver Cancer